RGT-61159
Sources
company_release, as of 2026-11-07
Rgenta Therapeutics release, 10.22.2026 (company release; opened 2026-10-27): end-of-Phase 2 meeting with FDA, alignment on Phase 3 of RGT-61159 in ACC; planned start 1Q 2027; double-blind, placebo-controlled, about 150 biomarker-selected patients, randomized 2:2:1 to 84 mg, 60 mg or placebo once daily, all with best supportive care; primary endpoint PFS; key secondary OS, safety, tolerability; North America and Europe. Phase 1a/b: disease control 84.6% (33 of 39) at or below RP2D, 3 partial responses. About 200,000 people live with ACC worldwide and 11,000 in the US (company figure).
Brief source A8
company_release, as of 2026-11-07
Rgenta Therapeutics release, 05.21.2026 (company release; opened 2026-10-27), ASCO 2026 abstract 3089 (doi 10.1200/jco.2026.44.16_suppl.3089; abstract not opened): 39 evaluable patients at or below RP2D, disease control 84.6% (33), 3 partial responses (2 confirmed, 1 pending confirmation); partial responders on study a mean 8.2 months; most common adverse events fatigue, anemia, diarrhea, nausea. Preliminary. The release gives no grade 3 or discontinuation rates; a grade 3 vasculitis at 144 mg noted in a search record of the abstract is not verified.
Brief source A10
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT06462183
A Phase 1a/1b, First-in-human, Multicenter Study to Assess the Efficacy and Safety of RGT-61159 for Treatment of Patients With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
ClinicalTrials.gov API v2 record, retrieved 2026-11-07